What is Swithro 200?
Swithro 200 injection is used to treat bacterial infections in many different parts of the body. It is also used to prevent Mycobacterium avium complex (MAC) disease in patients infected with the human immunodeficiency virus (HIV).
Swithro 200 belongs to the class of drugs known as macrolide antibiotics. It works by killing bacteria or preventing their growth. However, Swithro 200 will not work for colds, flu, or other virus infections. Swithro 200 injection may be used for other problems as determined by your doctor.
Swithro 200 is available only with your doctor's prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, Swithro 200 is used in certain patients with the following medical condition:
- Trachoma (treatment).
Swithro 200 indications
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Swithro 200 Tablets and other antibacterial drugs, Swithro 200 Tablets should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Swithro 200 Tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below.
Mycobacterial Infections
Prophylaxis of Disseminated Mycobacterium avium complex (MAC) Disease
Swithro 200 Tablets, taken alone or in combination with rifabutin at its approved dose, are indicated for the prevention of disseminated MAC disease in persons with advanced HIV infection.
Treatment of Disseminated MAC Disease
Swithro 200 Tablets, taken in combination with ethambutol, are indicated for the treatment of disseminated MAC infections in persons with advanced HIV infection.
How should I use Swithro 200?
Use Swithro 200 drops as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Swithro 200 drops. Talk to your pharmacist if you have questions about this information.
- Swithro 200 drops is for use in the eye only. Do not swallow it.
- Wash your hands immediately before you use Swithro 200 drops.
- To use Swithro 200 drops, turn the bottle upside down and shake once before each use. Remove the cap while the bottle is still upside down. Tilt your head back. Using your index finger, pull the lower eyelid away from the eye to form a pouch. Gently squeeze the bottle to drop the medicine into the pouch, then gently close your eyes. Immediately use your finger to apply pressure to the inside corner of the eye for 1 to 2 minutes. Do not blink. Remove excess medicine around your eye with a clean, dry tissue, being careful not to touch your eye. Wash your hands to remove any medicine that may be on them.
- If a drop does not come out of the bottle when using your dose, repeat these steps.
- To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including the eye. Keep the container tightly closed.
- Do not wear contact lenses while you are using Swithro 200 drops. Take care of your contact lenses as directed by the manufacturer. Check with your doctor before you use them.
- To clear up your infection completely, use Swithro 200 drops for the full course of treatment. Keep using it even if you feel better in a few days.
- If you miss a dose of Swithro 200 drops, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Swithro 200 drops.
Uses of Swithro 200 in details
Use: Labeled Indications
Oral, IV:
Chancroid: Treatment of genital ulcer disease (in men) due to Haemophilus ducreyi (chancroid)
Chronic obstructive pulmonary disease, acute exacerbation: Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae
Mycobacterium avium complex: Prevention of Mycobacterium avium complex (MAC) in patients with advanced HIV infection; treatment of disseminated MAC (in combination with ethambutol) in patients with advanced HIV infection
Otitis media, acute: Treatment of acute otitis media due to H. influenzae, M. catarrhalis, or S. pneumoniae
Pneumonia, community-acquired: Treatment of community-acquired pneumonia (CAP) due to Chlamydophila pneumoniae, H. influenzae, Legionella pneumophila, M. catarrhalis, Mycoplasma pneumoniae, or S. pneumoniae
Skin and skin structure infection, uncomplicated: Treatment of uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae
Streptococcal pharyngitis (group A): Treatment of pharyngitis/tonsillitis due to S. pyogenes as an alternative to first-line therapy
Urethritis/cervicitis: Treatment of urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae
Off Label Uses
Acne vulgaris
Data from controlled trials support the use of Swithro 200 in the treatment of acne vulgaris in adults with moderate to severe acne.
Based on the American Academy of Dermatology guidelines of care for the management of acne vulgaris, Swithro 200, in combination with topical therapy, may be considered as a treatment option for moderate and severe acne and forms of inflammatory acne that are resistant to topical treatments. However, its use should be limited to patients who cannot receive a tetracycline (ie, pregnant women). Concomitant topical therapy with benzoyl peroxide or a retinoid should be administered with systemic antibiotic therapy (eg, Swithro 200) and continued for maintenance after the antibiotic course is completed.
Babesiosis
Data from a prospective, nonblinded, randomized trial in patients with non-life-threatening babesiosis, support the use of Swithro 200 (in combination with atovaquone) for the treatment of this condition.
Based on the CDC Yellow Book, the ACG guideline for the diagnosis, treatment, and prevention of acute diarrheal infections in adults, and the IDSA practice guidelines for the diagnosis and management of infectious diarrhea, Swithro 200 is effective and recommended treatment for patients with travelers' diarrhea. Due to increased levels of resistance to fluoroquinolones, Swithro 200 may be a recommended first-line treatment, especially in regions with a high prevalence of Campylobacter (eg, Southeast Asia, India) or in geographical areas with suspected fluoroquinolone-resistant pathogens or enterotoxigenic Escherichia coli.
Swithro 200 description
Each film-coated tablet contains Azithromycin dihydrate equivalent to Swithro 200 500 mg.
Swithro 200 is a nitrogen-containing macrolide or azalide with actions and uses similar to those of erythromycin. Swithro 200 is derived from erythromycin. However, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring.
Swithro 200 dosage
Not for pediatric use.
For pediatric patients, please refer to the INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION sections of the prescribing information for Swithro 200 for oral suspension 100 mg/5 mL and 200 mg/5 mL bottles.
Swithro 200 Tablets may be taken without regard to food. However, increased tolerability has been observed when tablets are taken with food.
Mycobacterial Infections
Prevention of Disseminated MAC Infections
The recommended dose of Swithro 200 Tablets for the prevention of disseminated Mycobacterium avium complex (MAC) disease is: 1200 mg taken once weekly. This dose of Swithro 200 Tablets may be combined with the approved dosage regimen of rifabutin.
Treatment of Disseminated MAC Infections
Swithro 200 Tablets should be taken at a daily dose of 600 mg, in combination with ethambutol at the recommended daily dose of 15 mg/kg. Other antimycobacterial drugs that have shown in vitro activity against MAC may be added to the regimen of Swithro 200 plus ethambutol at the discretion of the physician or health care provider.
Swithro 200 interactions
See also:
What other drugs will affect Swithro 200?
Antacids: In a pharmacokinetic study investigating the effects of simultaneous administration of antacid with Swithro 200, no effects on overall bioavailability was seen although peak serum concentrations were reduced by up to 30%. In patients receiving both Swithro 200 and antacids, the drug should not be taken simultaneously.
Carbamazepine: In a pharmacokinetic interaction study in healthy volunteers, no significant effect was observed on the plasma levels of carbamazepine or its active metabolite in patients receiving concomitant Swithro 200.
Cimetidine: A single dose of cimetidine administered 2 hrs before Swithro 200 had no effect on the pharmacokinetics of Swithro 200.
Cyclosporin: In the absence of conclusive data from pharmacokinetics or clinical studies investigating potential interaction between Swithro 200 and cyclosporin, caution should be exercised before concurrent administration of these drugs. If co-administration of these drugs is necessary, cyclosporin levels should be monitored and the dose adjusted accordingly.
Digoxin: Some of the macrolide antibiotics have been reported to impair the metabolism of digoxin (in the gut) in some patients. Therefore, in patients receiving concomitant Swithro 200 and digoxin, the possibility of raised digoxin levels should be bourne in mind, and digoxin levels monitored.
Ergot Derivatives: Because of the theoretical possibility of ergotism, Swithro 200 and ergot derivatives should not be co-administered.
Methylprednisolone: In a pharmacokinetic interaction study in healthy volunteers, Swithro 200 had no significant effect on the pharmacokinetics of methylprednisolone.
Terfenadine: Pharmacokinetic studies have reported no evidence of an interaction between Swithro 200 and terfenadine. There have been rare cases reported where the possibility of such an interaction could not be entirely excluded; however, there was no specific evidence that such an interaction had occured.
Theophylline: There is no evidence of any pharmacokinetic interaction when Swithro 200 and theophylline are co-administered in healthy volunteers.
Coumarin-TypeOral Anticoagulants:
In a pharmacodynamic interaction study, Swithro 200 did not alter the anticoagulant effect of a single dose warfarin 15 mg administered to healthy volunteers. There have been reports received in the post-marketing period of potentiated anticoagulant subsequent to co-administration of Swithro 200 and coumarin-type oral anticoagulants. Although a causal relationship has not been established, consideration should be given to the frequency of monitoring prothrombin time when Swithro 200 is used in patients receiving coumarin-type oral anticoagulants.
Zidovudine: Single 1000 mg doses, and multiple 1200 mg or 600 mg doses of Swithro 200 did not affect the plasma pharmacokinetics or urinary excretion of zidovudine or its glucuronide metabolite. However, administration of Swithro 200 increased the concentrations of phosphorylated zidovudine, the clinically active metabolite, in peripheral blood mononuclear cells. The clinical significance of this finding is unclear, but it may be of benefit to patients.
Didanosine: Co-administration of daily doses of Swithro 200 1200 mg with didanosine in 6 subjects did not appear to affect the pharmacokinetics of didanosine as compared with placebo.
Rifabutin: Co-administration of Swithro 200 and rifabutin did not affect the serum concentrations of either drug. Neutropenia was observed in subjects receiving concomitant treatment of Swithro 200 and rifabutin. Although neutropenia has been associated with the use of rifabutin, a causal relationship to combination with Swithro 200 has not been established.
Swithro 200 side effects
See also:
What are the possible side effects of Swithro 200?
Applies to Swithro 200 ophthalmic: ophthalmic solution
In addition to its needed effects, some unwanted effects may be caused by Swithro 200 ophthalmic. In the event that any of these side effects do occur, they may require medical attention.
Major Side Effects
You should check with your doctor immediately if any of these side effects occur when taking Swithro 200 ophthalmic:
Less common:
- Burning, redness, stinging, or other eye irritation
- Blistering, burning, crusting, dryness, or flaking of the skin
- blurred vision
- cough
- decreased vision
- discharge from the eye
- fever
- headache
- hives or welts
- itching, scaling, severe redness, soreness, or swelling of the skin
- pain or tenderness around the eyes and cheekbones
- painful irritation of the clear front part of the eye
- shortness of breath or troubled breathing
- skin rash
- stuffy or runny nose
- swelling of the face
- swelling or puffiness of the eyes
- tightness of the chest or wheezing
Minor Side Effects
Some of the side effects that can occur with Swithro 200 ophthalmic may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
Rare
- Change in taste
- dry eyes
- loss of taste
Swithro 200 contraindications
See also:
What is the most important information I should know about Swithro 200?
Hypersensitivity
Swithro 200 Tablets are contraindicated in patients with known hypersensitivity to Swithro 200, erythromycin, any macrolide, or ketolide drug.
Hepatic Dysfunction
Swithro 200 Tablets are contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of Swithro 200.
Active ingredient matches for Swithro 200:
| Unit description / dosage (Manufacturer) | Price, USD |
| Swithro 200 15 ml Suspension | $ 0.11 |
List of Swithro 200 substitutes (brand and generic names): | |
| Swithro 100 | |
| Swithro 100 15 ml Suspension (Ind-Swift Limited) | $ 0.09 |
| SYSTHRAL | |
| SYSTHRAL 250MG TABLET 1 strip / 6 tablets each (Sysmed Laboratories Pvt Ltd) | $ 0.72 |
| SYSTHRAL 500MG TABLET 1 strip / 3 tablets each (Sysmed Laboratories Pvt Ltd) | $ 0.75 |
| Systhral 500mg Tablet (Sysmed Laboratories Pvt Ltd) | $ 0.25 |
| Syzil | |
| Syzil 500 mg Tablet (Syskem Pharmocrats.) | $ 0.31 |
| Syzil 250 mg Tablet (Syskem Pharmocrats.) | $ 0.15 |
| Tabsuv (India) | |
| Tabsuv 500mg TAB / 3 (Encore) | $ 0.71 |
| TABSUV tab 500 mg x 3's (Encore) | $ 0.71 |
| Tabsuv 500mg Tablet (Encore) | $ 0.24 |
| TABSUV TABLET | |
| TABSUV TABLET 1 strip / 3 tablets each (Encore Pharmaceuticals Inc.) | $ 0.71 |
| Tailite (China) | |
| Talcilina (Argentina) | |
| TAM (TRIDENT) | |
| TAM 250MG TABLET 1 strip / 6 tablets each (Trident Pharma) | $ 0.86 |
| Tanezox (Argentina) | |
| Tanzin DT | |
| Tanzin DT 250 mg Tablet (Royal Sapphire Remedies) | $ 0.12 |
| Tanzin DT 500 mg Tablet (Royal Sapphire Remedies) | $ 0.23 |
| Tazi | |
| Tazi 500 mg Tablet (Tavis Lifecare) | $ 0.31 |
| Tazi 250 mg Tablet (Tavis Lifecare) | $ 0.14 |
| TAZIX | |
| TAZIX 100MG SYRUP 1 bottle / 15 ML syrup each (Ranbaxy Laboratories Ltd) | $ 0.31 |
| TAZIX 200MG SYRUP 1 bottle / 15 ML syrup each (Ranbaxy Laboratories Ltd) | $ 0.40 |
| TAZIX 250MG TABLET 1 strip / 6 tablets each (Ranbaxy Laboratories Ltd) | $ 0.72 |
| TAZIX 500MG TABLET 1 strip / 3 tablets each (Ranbaxy Laboratories Ltd) | $ 0.76 |
| Tazix 200mg Syrup (Sun Pharmaceutical Industries Ltd) | $ 0.40 |
| Tazix 250mg Tablet (Sun Pharmaceutical Industries Ltd) | $ 0.12 |
| Tazix 500mg Tablet (Sun Pharmaceutical Industries Ltd) | $ 0.25 |
| Te Li Xin (China) | |
| TECAZI | |
| TECAZI 500MG TABLET 1 strip / 3 tablets each (United Biotech Pvt Ltd) | $ 0.75 |
| Teozi (India) | |
| Teozi 250mg TAB / 6 (Swaraj) | $ 0.87 |
| Teozi 500mg TAB / 3 (Swaraj) | $ 0.65 |
| Teozi 100mg x 5mL SUSP / 15ml (Swaraj) | $ 0.35 |
| TEOZI tab 250 mg x 6's (Swaraj) | $ 0.87 |
| TEOZI tab 500 mg x 3's (Swaraj) | $ 0.65 |
| TEOZI oral susp 100 mg x 5 mL x 15ml (Swaraj) | $ 0.35 |
| Terry White Chemists Azithromycin (Australia) | |
| Tetris (Italy) | |
| Tetris 100's | $ 67.58 |
| Teva-Azithromycin (Canada) | |
| Texis (Mexico) | |
| Tablet, Film-Coated; Oral; Azithromycin Dihydrate 500 mg (Atlantis) | |
| Tablets, Film-Coated; Oral; Azithromycin Dihydrate 500 mg (Atlantis) | |
| Thiza (Bangladesh) | |
| Thoraxx (Croatia (Hrvatska), Greece) | |
| Thraz (India) | |
| Thraz 250mg TAB / 60 (Acme Skin Care Pvt Ltd) | $ 10.00 |
| Thraz 500mg TAB / 30 (Acme Skin Care Pvt Ltd) | $ 9.76 |
See 7409 substitutes for Swithro 200 | |
References
- DailyMed. "AZITHROMYCIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "azithromycin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "azithromycin". http://www.drugbank.ca/drugs/DB00207 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Swithro 200 are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Swithro 200. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
